Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sorafenib + bevacizumab + paclitaxel
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
b-Safi Shahda-solid tumor refers to a combination therapy regimen consisting of the multikinase inhibitor sorafenib, the anti-VEGF monoclonal antibody bevacizumab, and the microtubule-stabilizing cytotoxic agent paclitaxel. This specific combination was evaluated in a Phase I dose-escalation and drug-interaction study (NCT00933803) led by investigator Safi Shahda at Indiana University for the treatment of advanced solid tumors. The regimen was designed to leverage the synergistic effects of inhibiting multiple signaling pathways involved in tumor cell proliferation and angiogenesis (via sorafenib and bevacizumab) while utilizing the antimitotic properties of paclitaxel. The study primarily focused on determining the safety, tolerability, and maximum tolerated dose (MTD) of this triplet combination in patients with refractory malignancies.
- Brand names
- NexavarAvastinTaxol
- Other names
- b-Safi Shahda-solid tumorSorafenib, Bevacizumab, and Paclitaxel combinationNCT00933803 regimenNCT-00933803 regimenNCT 00933803 regimen
02
Targets
VEGFR4 (Vascular endothelial growth factor Receptor-3)PDGFRB (Platelet-derived growth factor receptor beta)TUBB (Tubulin (alpha and beta subunits))KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFA (Vascular endothelial growth factor A)FLT3 (Fms related receptor tyrosine kinase 3)BRAF V600ERAF1 (c-Raf-1 (Y340D/Y341D))VEGFR-1 (Vascular endothelial growth factor receptor 1)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on sorafenib + bevacizumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sorafenib + bevacizumab + paclitaxel.